Cargando…

Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model

Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Fei-lin, Si, Lan-lan, Yang, Yan, Li, Yuan-hua, Lv, Zhong-lin, Liu, Wen-hui, Liao, Hao, Wang, Jun, Zou, Jun, Li, Le, Li, Hui, Zhang, Zi-lin, Wang, Jia-bo, Lu, Xue-chun, Xu, Dong-ping, Bai, Zhao-fang, Liu, Yan, Xiao, Xiao-he
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578813/
https://www.ncbi.nlm.nih.gov/pubmed/34776974
http://dx.doi.org/10.3389/fphar.2021.756975
_version_ 1784596313667534848
author Ge, Fei-lin
Si, Lan-lan
Yang, Yan
Li, Yuan-hua
Lv, Zhong-lin
Liu, Wen-hui
Liao, Hao
Wang, Jun
Zou, Jun
Li, Le
Li, Hui
Zhang, Zi-lin
Wang, Jia-bo
Lu, Xue-chun
Xu, Dong-ping
Bai, Zhao-fang
Liu, Yan
Xiao, Xiao-he
author_facet Ge, Fei-lin
Si, Lan-lan
Yang, Yan
Li, Yuan-hua
Lv, Zhong-lin
Liu, Wen-hui
Liao, Hao
Wang, Jun
Zou, Jun
Li, Le
Li, Hui
Zhang, Zi-lin
Wang, Jia-bo
Lu, Xue-chun
Xu, Dong-ping
Bai, Zhao-fang
Liu, Yan
Xiao, Xiao-he
author_sort Ge, Fei-lin
collection PubMed
description Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mechanisms. HepG2.2.15 cells (wild-type HBV-replicating cells) and HepG2. A64 cells (entecavir-resistant HBV-replicating cells) were used for in vitro test. Hydrodynamic injection-mediated HBV-replicating mouse model was used for in vivo test. Active compounds and related mechanisms for antiviral effect of LWWL were analyzed using network pharmacology and transcriptomics. The inhibition rates of LWWL (0.8 mg/ml) on HBV DNA, HBsAg, and pgRNA were 57.06, 38.55, and 62.49% in HepG2.2.15 cells, and 51.57, 17.57, and 53.88% in HepG2. A64 cells, respectively. LWWL (2 g kg(−1) d(−1) for 4 weeks)-treated mice had 1.16 log(10) IU/mL decrease of serum HBV DNA, and more than 50% decrease of serum HBsAg/HBeAg and hepatic HBsAg/HBcAg. Compared to tenofovir control, LWWL was less effective in suppressing HBV DNA but more effective in suppressing HBV antigens. Thirteen differentially-expressed genes were found in relation to HBV-host interaction and some of them were enriched in interferon (IFN)-β pathway in LWWL-treated HepG2.2.15 cells. CD3(+)CD4(+) T-cell frequency and serum IFN-γ were significantly increased in LWWL-treated mice compared to LWWL-untreated mice. Among 26 compounds with potential anti-HBV effects that were predicted by network pharmacology, four compounds (quercetin, luteolin, wogonin, and kaempferol) were experimentally confirmed to have antiviral potency. In conclusion, LWWL had potent inhibitory effect on both wild-type and entecavir-resistant HBV, which might be associated with increasing IFN-β and IFN-γ production.
format Online
Article
Text
id pubmed-8578813
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85788132021-11-11 Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model Ge, Fei-lin Si, Lan-lan Yang, Yan Li, Yuan-hua Lv, Zhong-lin Liu, Wen-hui Liao, Hao Wang, Jun Zou, Jun Li, Le Li, Hui Zhang, Zi-lin Wang, Jia-bo Lu, Xue-chun Xu, Dong-ping Bai, Zhao-fang Liu, Yan Xiao, Xiao-he Front Pharmacol Pharmacology Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mechanisms. HepG2.2.15 cells (wild-type HBV-replicating cells) and HepG2. A64 cells (entecavir-resistant HBV-replicating cells) were used for in vitro test. Hydrodynamic injection-mediated HBV-replicating mouse model was used for in vivo test. Active compounds and related mechanisms for antiviral effect of LWWL were analyzed using network pharmacology and transcriptomics. The inhibition rates of LWWL (0.8 mg/ml) on HBV DNA, HBsAg, and pgRNA were 57.06, 38.55, and 62.49% in HepG2.2.15 cells, and 51.57, 17.57, and 53.88% in HepG2. A64 cells, respectively. LWWL (2 g kg(−1) d(−1) for 4 weeks)-treated mice had 1.16 log(10) IU/mL decrease of serum HBV DNA, and more than 50% decrease of serum HBsAg/HBeAg and hepatic HBsAg/HBcAg. Compared to tenofovir control, LWWL was less effective in suppressing HBV DNA but more effective in suppressing HBV antigens. Thirteen differentially-expressed genes were found in relation to HBV-host interaction and some of them were enriched in interferon (IFN)-β pathway in LWWL-treated HepG2.2.15 cells. CD3(+)CD4(+) T-cell frequency and serum IFN-γ were significantly increased in LWWL-treated mice compared to LWWL-untreated mice. Among 26 compounds with potential anti-HBV effects that were predicted by network pharmacology, four compounds (quercetin, luteolin, wogonin, and kaempferol) were experimentally confirmed to have antiviral potency. In conclusion, LWWL had potent inhibitory effect on both wild-type and entecavir-resistant HBV, which might be associated with increasing IFN-β and IFN-γ production. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8578813/ /pubmed/34776974 http://dx.doi.org/10.3389/fphar.2021.756975 Text en Copyright © 2021 Ge, Si, Yang, Li, Lv, Liu, Liao, Wang, Zou, Li, Li, Zhang, Wang, Lu, Xu, Bai, Liu and Xiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ge, Fei-lin
Si, Lan-lan
Yang, Yan
Li, Yuan-hua
Lv, Zhong-lin
Liu, Wen-hui
Liao, Hao
Wang, Jun
Zou, Jun
Li, Le
Li, Hui
Zhang, Zi-lin
Wang, Jia-bo
Lu, Xue-chun
Xu, Dong-ping
Bai, Zhao-fang
Liu, Yan
Xiao, Xiao-he
Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title_full Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title_fullStr Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title_full_unstemmed Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title_short Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
title_sort chinese patent medicine liuweiwuling tablet had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis b virus (hbv) in vitro and effectively suppressed hbv replication in mouse model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578813/
https://www.ncbi.nlm.nih.gov/pubmed/34776974
http://dx.doi.org/10.3389/fphar.2021.756975
work_keys_str_mv AT gefeilin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT silanlan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT yangyan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT liyuanhua chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT lvzhonglin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT liuwenhui chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT liaohao chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT wangjun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT zoujun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT lile chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT lihui chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT zhangzilin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT wangjiabo chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT luxuechun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT xudongping chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT baizhaofang chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT liuyan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel
AT xiaoxiaohe chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel